Phaseline

Companies › Regend Therapeutics

Regend Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
REGEND003
Human kidney progenitor cells for kidney injury repair
–Phase 1Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07275788REGEND003Phase 1Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)GenitourinaryDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.